Compare Stocks: APLM, HURA, ADCT, and CNTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.01 -4.3%	$1.15	$0.78 ▼ $4.98	$128.46M	1.89	875,058 shs	1.34 million shs
APLM Apollomics	$22.54 +29.8%	$18.06	$3.66 ▼ $42.12	$51.39M	1.46	28,911 shs	47,633 shs
CNTB Connect Biopharma	$2.55 +0.4%	$2.21	$1.23 ▼ $3.82	$160.56M	-0.23	341,923 shs	212,178 shs
HURA TuHURA Biosciences	$2.47 +7.4%	$2.28	$0.41 ▼ $3.43	$157.30M	-0.01	235,478 shs	317,089 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-10.59%	-25.28%	-69.15%	-67.48%
APLM Apollomics	0.00%	+28.06%	-3.15%	+54.48%	+288.59%
CNTB Connect Biopharma	0.00%	+15.91%	+8.97%	+7.14%	+8.05%
HURA TuHURA Biosciences	0.00%	+15.96%	+11.26%	+6.93%	-13.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.01 -4.3%	$1.15	$0.78 ▼ $4.98	$128.46M	1.89	875,058 shs	1.34 million shs
APLM Apollomics	$22.54 +29.8%	$18.06	$3.66 ▼ $42.12	$51.39M	1.46	28,911 shs	47,633 shs
CNTB Connect Biopharma	$2.55 +0.4%	$2.21	$1.23 ▼ $3.82	$160.56M	-0.23	341,923 shs	212,178 shs
HURA TuHURA Biosciences	$2.47 +7.4%	$2.28	$0.41 ▼ $3.43	$157.30M	-0.01	235,478 shs	317,089 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-10.59%	-25.28%	-69.15%	-67.48%
APLM Apollomics	0.00%	+28.06%	-3.15%	+54.48%	+288.59%
CNTB Connect Biopharma	0.00%	+15.91%	+8.97%	+7.14%	+8.05%
HURA TuHURA Biosciences	0.00%	+15.96%	+11.26%	+6.93%	-13.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$6.25	521.89% Upside
APLM Apollomics	1.00	Sell	N/A	N/A
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	191.32% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	264.37% Upside

Current Analyst Ratings Breakdown

Latest APLM, HURA, ADCT, and CNTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	HURA TuHURA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/9/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
6/30/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00
6/25/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
6/23/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.57	N/A	N/A	($1.50) per share	-0.67
APLM Apollomics	$8.50M	5.83	N/A	N/A	($2.89) per share	-7.80
CNTB Connect Biopharma	$60K	2,675.80	N/A	N/A	$0.43 per share	5.93
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.15%	N/A
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	N/A
HURA TuHURA Biosciences	-$30.05M	-$0.61	N/A	N/A	N/A	N/A	-156.12%	-105.38%	N/A

Latest APLM, HURA, ADCT, and CNTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/13/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
5/15/2026	Q1 2026	HURA TuHURA Biosciences	-$0.12	-$0.13	-$0.01	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.09	4.02
APLM Apollomics	N/A	0.96	0.96
CNTB Connect Biopharma	0.01	2.37	3.23
HURA TuHURA Biosciences	N/A	1.15	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
APLM Apollomics	19.13%
CNTB Connect Biopharma	58.72%
HURA TuHURA Biosciences	0.62%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
APLM Apollomics	N/A
CNTB Connect Biopharma	22.60%
HURA TuHURA Biosciences	6.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.19 million	120.70 million	Optionable
APLM Apollomics	45	2.20 million	N/A	Not Optionable
CNTB Connect Biopharma	110	62.96 million	48.73 million	Optionable
HURA TuHURA Biosciences	N/A	63.68 million	59.82 million	N/A

APLM, HURA, ADCT, and CNTB Headlines

Recent News About These Companies

TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

August 14 at 7:55 PM | marketbeat.com

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

August 14 at 11:04 AM | marketbeat.com

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

August 14 at 7:45 AM | prnewswire.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

August 13 at 5:51 PM | tipranks.com

TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

TuHURA Biosciences Expands Revolving Credit Facility Utilization

July 29, 2026 | tipranks.com

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Moderate Buy" from Analysts

July 24, 2026 | marketbeat.com

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

July 22, 2026 | prnewswire.com

TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 1.3% - Time to Sell?

July 22, 2026 | marketbeat.com

TuHURA Biosciences Expands Use of Revolving Credit Facility

July 7, 2026 | tipranks.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets ...

June 16, 2026 | finanznachrichten.de

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood ...

June 15, 2026 | finance.yahoo.com

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

June 15, 2026 | prnewswire.com

TuHURA Biosciences Draws on New $50M Credit Facility

May 29, 2026 | tipranks.com

HURA: Refining TBS-2025 development plan

May 26, 2026 | msn.com

TuHURA Biosciences, Inc.: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 16, 2026 | finanznachrichten.de

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 15, 2026 | prnewswire.com

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026 | prnewswire.com

Citizens Initiates Coverage of TuHURA Biosciences (HURA) with Market Outperform Recommendation

April 28, 2026 | msn.com

TuHURA Biosciences Secures $50 Million Credit Facility

April 22, 2026 | tipranks.com

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

April 22, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM, HURA, ADCT, and CNTB Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.00 -0.05 (-4.29%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$1.01 +0.01 (+0.50%)

As of 08/14/2026 07:59 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Apollomics NASDAQ:APLM

$22.54 +5.17 (+29.75%)

Closing price 08/14/2026 03:58 PM Eastern

Extended Trading

$21.86 -0.68 (-3.01%)

As of 08/14/2026 07:34 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Connect Biopharma NASDAQ:CNTB

$2.55 +0.01 (+0.39%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.52 -0.02 (-0.98%)

As of 08/14/2026 07:50 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

TuHURA Biosciences NASDAQ:HURA

$2.47 +0.17 (+7.39%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.46 -0.01 (-0.36%)

As of 08/14/2026 07:36 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLM, HURA, ADCT, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLM, HURA, ADCT, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLM, HURA, ADCT, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM, HURA, ADCT, and CNTB Company Descriptions

ADC Therapeutics NYSE:ADCT

Apollomics NASDAQ:APLM

Connect Biopharma NASDAQ:CNTB

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLM, HURA, ADCT, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLM, HURA, ADCT, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLM, HURA, ADCT, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM, HURA, ADCT, and CNTB Company Descriptions

ADC Therapeutics NYSE:ADCT

Apollomics NASDAQ:APLM

Connect Biopharma NASDAQ:CNTB

TuHURA Biosciences NASDAQ:HURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools